Lilly’s Eczema Contender Promising, But Needs Head-To-Head Data To Dent Dupixent Dominance

Also Vital For Partners Almirall

Topline results suggest lebrikizumab could outshine Sanofi’s Dupixent on safety and itch reduction in atopic eczema, but a direct comparison study is likely required to drive the message home.

Lilly is also awaiting FDA judgement on its JAK inhibitor Olumiant in atopic dermatitis, a fast expanding market for biologics.

Eli Lilly and Company and Almirall have released promising topline Phase III data from their anti-IL13 candidate lebrikizumab in eczema treatment, but will probably need to conduct a head-to-head trial to challenge the dominance of Dupixent in the market.

The data released showed that lebrikizumab resulted in at least 75% skin clearance in “more than half” of people with...